NFLX
74
4
CSX
43
3
CCL
60
2
TRV
42
5
RSG
56
2
RHI
50
2
PFG
30
3
KEY
27
3
NWSA
75
8
CL
50
3
PX
58
5
MUR
43
3
MCK
59
3
PFE
33
-2
CPB
27
5
ETR
65
4
WMB
62
2
ROK
48
2
HOG
29
2
NDAQ
50
4
NFLX
74
4
CSX
43
3
CCL
60
2
TRV
42
5
RSG
56
2
RHI
50
2
PFG
30
3
KEY
27
3
NWSA
75
8
CL
50
3
PX
58
5
MUR
43
3
MCK
59
3
PFE
33
-2
CPB
27
5
ETR
65
4
WMB
62
2
ROK
48
2
HOG
29
2
NDAQ
50
4
Financhill
Back

Zevra Therapeutics 10K Form

Sell
48

ZVRA
Zevra Therapeutics

Last Price:
$8.56
Seasonality Move:
-0.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $27.5M
Cash Flow: $-18.1M
Price / Cash Flow: 0
Annual Sales: $1.31
Price / Book: 6.57

Profitability

EPS (TTM): -2.11000
Net Income (TTM): $-89.7M
Gross Margin: $24.5M
Return on Equity: -159.89%
Return on Assets: -56.14%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for ZVRA is 89.28%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 124.96% of Gross Profit Margin.
  • The Research & Development expenses have been 144.95% of Revenue.
  • The Interest Expense is -3.26% of Operating Income.
  • The Net Earning history of ZVRA is -167.69% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 2.88
Quick Ratio: 2.82

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ZVRA Technical Analysis vs Fundamental Analysis

Sell
48
Zevra Therapeutics (ZVRA) is a Sell

Is Zevra Therapeutics a Buy or a Sell?